Cite
MLA Citation
Michèle Voegeli et al.. “Y90‐Ibritumomab tiuxetan (Y90‐IT) and high‐dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05).” Hematological oncology, vol. 35, no. 4, n.d., pp. 576–583. http://access.bl.uk/ark:/81055/vdc_100055218731.0x000046